DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.
These analyses are performed through simultaneous examination of millions of DNA sequences using machine learning to identify tumor-specific abnormalities. Because genome-wide fragmentation patterns can also reveal differences between cancer types, DELFI not only detects cancer but can also identify the cancers’ tissue of origin.
Genome-wide cell-free DNA fragmentation in patients with cancer
Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SØ, Medina JE, Hruban C, White JR, Palsgrove DN, Niknafs N, Anagnostou V, Forde P, Naidoo J, Marrone K, Brahmer J, Woodward BD, Husain H, van Rooijen KL, Ørntoft MW, Madsen AH, van de Velde CJH, Verheij M, Cats A, Punt CJA, Vink GR, van Grieken NCT, Koopman M, Fijneman RJA, Johansen JS, Nielsen HJ, Meijer GA, Andersen CL, Scharpf RB, Velculescu VE.
Nature, June 2019, 570 (7761): 385-389